{"@context":{"@vocab":"https://cir.nii.ac.jp/schema/1.0/","rdfs":"http://www.w3.org/2000/01/rdf-schema#","dc":"http://purl.org/dc/elements/1.1/","dcterms":"http://purl.org/dc/terms/","foaf":"http://xmlns.com/foaf/0.1/","prism":"http://prismstandard.org/namespaces/basic/2.0/","cinii":"http://ci.nii.ac.jp/ns/1.0/","datacite":"https://schema.datacite.org/meta/kernel-4/","ndl":"http://ndl.go.jp/dcndl/terms/","jpcoar":"https://github.com/JPCOAR/schema/blob/master/2.0/"},"@id":"https://cir.nii.ac.jp/crid/1361699993396398080.json","@type":"Article","productIdentifier":[{"identifier":{"@type":"DOI","@value":"10.1111/j.1749-6632.2000.tb05452.x"}},{"identifier":{"@type":"URI","@value":"https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1111%2Fj.1749-6632.2000.tb05452.x"}},{"identifier":{"@type":"URI","@value":"https://nyaspubs.onlinelibrary.wiley.com/doi/pdf/10.1111/j.1749-6632.2000.tb05452.x"}}],"dc:title":[{"@value":"Androstenetriol and Androstenediol: Protection Against Lethal Radiation and Restoration of Immunity After Radiation Injury"}],"description":[{"type":"abstract","notation":[{"@value":"<jats:p><jats:bold>A<jats:sc>bstract</jats:sc>: </jats:bold> Androstenetriol (AET) and Androstenediol (AED) upregulate host immunity, leading to increased resistance against infections. AET augments IL‐2, IL‐3, IFNγ levels, and counteracts hydrocortisone immune suppression. AET and AED at a dose of 0.75 mg/‐ and 8.0 mg/25‐g mouse, protected 60 and 70%, respectively, of C57/BL/6J mice irradiated with a lethal dose. These hormones also protected mice irradiated with 6 Gy and infected with a coxsackievirus B4 LD50. AET significantly increased spleen lymphocyte numbers at 7, 14, and 21 days after a 6‐Gy exposure. Fluorescent activated cell‐sorter analysis of irradiated mice, spleen, and bone marrow showed that AET significantly augmented the myeloid precursor markers, CD11b/Mac‐1, and B220 (pan B), as well as the absolute numbers of CD4+/CD8+ cells over the 21 days of testing. Overall, the data are consistent with AET/AED inducing a more rapid recovery of all hematopoietic precursors from the small number of surviving stem cells.</jats:p>"}]}],"creator":[{"@id":"https://cir.nii.ac.jp/crid/1381699993396397952","@type":"Researcher","foaf:name":[{"@value":"R. M. LORIA"}]},{"@id":"https://cir.nii.ac.jp/crid/1381699993396397954","@type":"Researcher","foaf:name":[{"@value":"D. H. CONRAD"}]},{"@id":"https://cir.nii.ac.jp/crid/1381699993396397953","@type":"Researcher","foaf:name":[{"@value":"T. HUFF"}]},{"@id":"https://cir.nii.ac.jp/crid/1381699993396398080","@type":"Researcher","foaf:name":[{"@value":"H. CARTER"}]},{"@id":"https://cir.nii.ac.jp/crid/1380861290662313216","@type":"Researcher","foaf:name":[{"@value":"D. BEN‐NATHAN"}]}],"publication":{"publicationIdentifier":[{"@type":"PISSN","@value":"00778923"},{"@type":"EISSN","@value":"17496632"},{"@type":"PISSN","@value":"http://id.crossref.org/issn/00778923"}],"prism:publicationName":[{"@value":"Annals of the New York Academy of Sciences"}],"dc:publisher":[{"@value":"Wiley"}],"prism:publicationDate":"2000-01","prism:volume":"917","prism:number":"1","prism:startingPage":"860","prism:endingPage":"867"},"reviewed":"false","dc:rights":["http://onlinelibrary.wiley.com/termsAndConditions#vor"],"url":[{"@id":"https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1111%2Fj.1749-6632.2000.tb05452.x"},{"@id":"https://nyaspubs.onlinelibrary.wiley.com/doi/pdf/10.1111/j.1749-6632.2000.tb05452.x"}],"createdAt":"2010-07-20","modifiedAt":"2023-09-25","relatedProduct":[{"@id":"https://cir.nii.ac.jp/crid/1390001204288581120","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Overview of Radiation-protective Agent Research and Prospects for the Future"}]},{"@id":"https://cir.nii.ac.jp/crid/1390282679601281664","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Serum Concentrations of .DELTA.5-3.BETA.-Hydroxysteroids in Type 2 Diabetes Mellitus."},{"@value":"Serum Concentrations of Δ5-3β-Hydroxysteroids in Type 2 Diabetes Mellitus"},{"@language":"ja-Kana","@value":"Serum Concentrations of デルタ 5 3 ベータ Hydroxysteroids in Type 2 Diabetes Mellitus"}]}],"dataSourceIdentifier":[{"@type":"CROSSREF","@value":"10.1111/j.1749-6632.2000.tb05452.x"},{"@type":"CROSSREF","@value":"10.5453/jhps.52.285_references_DOI_63Qy4lgo5ZuVtZORL7fK0CSVief"},{"@type":"CROSSREF","@value":"10.1248/bpb.25.1634_references_DOI_63Qy4lgo5ZuVtZORL7fK0CSVief"}]}